The Maverick™ Diagnostic System (MDS) uses
silicon chip-based photonic ring resonator
technology to perform multiple simultaneous
rapid tests on a small volume of whole
blood or serum. The system is cloud-connected
for assay protocol retrieval and clinical
Maverick™ Immunoassay Analyzer
- Benchtop solution available for On-Site or Core Laboratory testing as well as integrated in Merlin
- Runs four patients simultaneously
- Runs up to 26 tests on a single drop of blood
- 250 patients/day
- High sensitivity and specificity
- Cloud-connected with CLIA/CAP pathology oversight
11” high X 16″ wide X 23″ deep
Photonic Ring Resonator Technology
Genalyte has developed multiplex assay detection technology based on silicon photonics that uses ring resonance to measure binding of macromolecules to sensors on a miniature silicon chip. The Maverick™ Diagnostic System detects changes in resonance wavelength as macromolecules, such as autoantibodies, bind to their respective antigens that are bound to the chip; eliminating the need for fluorescent, luminescent, or radioactive labels used in other immunoassay formats.
SARS-CoV-2 Multi-Antigen Serology Panel
Genalyte’s SARS-CoV-2 antibody test measures reactivity levels for 26 IgG and IgM antibody targets with market leading performance.
Tested by Northshore University, Mayo Clinic, and Scripps, Genalyte’s SARS-CoV-2 antibody test had the highest sensitivity and specificity as compared to central lab machines.
How It Works
Watch Maverick™ Technology In Action
31 Patent Issued and 17 Pending
Our proprietary Marverick™ Diagnostic System (MDS) has 31 patents issued and 17 patents pending worldwide.
FDA Clearance and EUA Authorization
The MaverickTM Diagnostic System (MDS) received FDA clearance for RNP (ribonuceloprotein) assay in October 2019.
In addition, the MaverickTM Diagnostic System (MDS) received Emergency Use Authorization (EUA) by the FDA for SARS-CoV-2 Multi-Antigen Serology Panel in October 2020